The effect of Aripiprazol and Perfenazinpatients on biochemical factors among patients with bipolar disorder

Comparing changes of biochemical factors in serum of patients with bipolar disorder who received Aripiprazol versus Perfenazin

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170606034348N6

Enrollment

Registered

2020-03-03

Start date

2019-05-22

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar disorder

Interventions

Intervention 1: Intervention group1:Aripiprazole, 10 mg tablet (produced by Jalinous Company) with dose range of 10-30 and Sodium Valproate 200 mg tablet (produced by Hakim Company) for 3 months. Inte

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: No Psychotic symptom Bipolar disorder diagnosis based on DSM-4-TR Filling in the personal satisfaction form Ages between 18-50 years

Exclusion criteria

Exclusion criteria: Hypertension High blood lipids Antihypertensive and antihypertensive drugs Diabetes mellitus type-II Physical disorders Pregnancy

Design outcomes

Primary

Measure	Time frame
Fasting Blood Suger. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;Triglyceride. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;Cholesterol. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;HDL. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;LDL. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.	—

Measure

Time frame

Fasting Blood Suger. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;Triglyceride. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;Cholesterol. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;HDL. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.;LDL. Timepoint: Before treatment and three months after treatment. Method of measurement: Laboratory test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Angela Hamidia

Babol University of Medical Sciences

angela_7633@yahoo.com+98 11 3229 1951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026